1103738-26-6

Basic information

• Product Name: (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone
• Synonyms: (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone;(2-chloro-5-iodophenyl)(4-ethoxyphenyl)methanone;Methanone,(2-chloro-5-iodophenyl)(4-ethoxyphenyl)-
• CAS NO: 1103738-26-6
• Molecular Formula: C₁₅H₁₂ClIO₂
• Molecular Weight: 386.61205
• Mol File: 1103738-26-6.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 461.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.597±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone(1103738-26-6)
• EPA Substance Registry System: (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone(1103738-26-6)

Safety Data

• Hazardous Substances Data: 1103738-26-6(Hazardous Substances Data)

Usage

General Description

(5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone is a chemical compound with the molecular formula C15H12ClIO2. It consists of a benzophenone core with a 5-iodo-2-chlorophenyl group and a 4-ethoxyphenyl group attached to it. (5-Iodo-2-chlorophenyl)(4-ethoxyphenyl)methanone is used in organic synthesis and medicinal chemistry research. It has been studied for its potential pharmaceutical applications, such as in the development of new drugs for various medical conditions. Additionally, due to its unique structure and properties, it may also have potential uses in other areas, such as material science or chemical engineering.

Upstream product

• 281652-58-2 2-chloro-5-iodobenzoylchloride 
• 103-73-1 Phenetole 
• 19094-56-5 2-chloro-5-iodobenzoic acid 
• 462-06-6 fluorobenzene 
• 915095-86-2 (2-chloro-5-iodophenyl)(4-fluorophenyl)methanone 
• 64-17-5 ethanol 
• 2388-07-0 lithium ethoxide 
• 917-58-8 potassium ethoxide 
• 141-52-6 sodium ethanolate 

Downstream Products

• 1103738-29-9 1-chloro-2-(4-ethoxybenzyl)-4-iodobenzene 
• 1018899-04-1 (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylsulfanyl)tetrahydro-2-H-pyran-3,4,5-triol 
• 1018899-03-0 [(2S,3S,4R,5S,6R)-4,5-diacetoxy-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylthiotetrahydropyran-3-yl]acetate 
• 1018898-84-4 acetic acid (3S,4R,5S,6S)-2,4,5-triacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydropyran-3-yl ester 
• 1103738-30-2 (4-chloro-3-(4-ethoxybenzyl)phenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuran[2,3-d][1,3]dioxolan-5-yl)methanone 
• 1459754-40-5 (2-chloro-5-iodophenyl)(4-hydroxyphenyl)methanone 
• 1417573-74-0 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucopyranoside 
• 915095-99-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-trityl triacetate 
• 1079083-63-8 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-hydroxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 461432-25-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 461432-26-8 dapagliflozin 

Relevant articles and documents

Design, synthesis and anticancer activities of halogenated Phenstatin analogs as microtubule destabilizing agent

A series of halogenated Phenstatin analogs were designed as microtubule destabilizing agent by docking study. It was synthesized within three steps starting from 2-chloro-5-iodobenzoic acid and substituted benzene. All the products were characterized by 1H NMR and 13C NMR spectral analysis, and the stereochemical structure was also confirmed by a single crystal X-ray diffraction crystallographic analysis. The microtubule destabilizing activities were evaluated in vitro with human liver cancer Huh-7 cell line and human lung cancer A549 cell line. Some of the HPAs were achieved IC50 about 5.0 μM against human liver cancer Huh-7 cells. [Figure not available: see fulltext.].

Preparation method of polysubstituted diphenyl ketone

The preparation method comprises the following steps: (1) a compound represented by the formula II and a compound shown III as a raw material; and synthesizing the compound as shown IV. (2) The compound of Formula IV is subjected to Fries rearrangement to produce a compound of Formula V. (3) A compound of Formula V is subjected to a halogenation reaction in contact with a halogenation reagent to prepare a multi-substituted diphenyl ketone represented by Formula I. Wherein, X is selected from H, F, Cl, Br, I. R1 Selected H from F Cl, Br I are RO selected R from H, C1 - C6. X is selected from F, Cl, Br, and i. The present invention is capable of improving the yield and selectivity of the target product.

Process development of sotagliflozin, a dual inhibitor of sodium- Glucose cotransporter-1/2 for the treatment of diabetes

The development of an efficient manufacturing process for sotagliflozin (LX4211), a dual inhibitor of sodium- glucose cotransporter-1/2 (SGLT-1/2) for the treatment of diabetes, is described. Sotagliflozin features five contiguous chiral centers on the carbohydrate core flanked by a thioether group and a biaryl moiety. Three chiral centers are obtained from the starting material L-xylose, while the other two were established (or modified) via three highly stereoselective transformations: Luche reduction (dr: 97/3), dynamic kinetic resolution of anomeric hemiacetal (dr: 95/5), and Lewis acid-promoted thiolation (dr: 1000/ 1). Global deprotection of the resulting penultimate intermediate with catalytic sodium methoxide followed by recrystallization furnishes sotagliflozin. The longest linear sequence consists of 10 steps from L-xylose with an overall yield of 40%. This process has been performed on multi-hundred kilogram batches to satisfy the drug substance development demands.